Parkinson’s disease remains one of the most challenging neurodegenerative disorders, with current treatments offering partial and temporary relief. A new experimental study from the University of Guadalajara investigated whether bee venom could serve as an adjunct to standard therapy. Using a mouse model of Parkinson’s disease, the team examined whether combining bee venom with L-DOPA/carbidopa could improve motor and cognitive outcomes. The findings provide encouraging behavioral evidence, supporting further research into this unconventional therapeutic approach.

The brain continuously produces metabolic waste that must be removed to maintain healthy function. Cerebrospinal fluid (CSF) plays a central role in this process by carrying away proteins such as amyloid-β, phosphorylated tau, and α-synuclein, which are linked to Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders when they accumulate abnormally.

Scientists have long known that much of this waste ultimately leaves the brain through lymphatic vessels and drains into lymph nodes in the neck. Yet one fundamental question has remained unanswered: How does cerebrospinal fluid cross the arachnoid membrane, a protective barrier separating the brain from the surrounding lymphatic system?

A research team led by Director KOH Gou Young at the Center for Vascular Research within the Institute for Basic Science (IBS), together with collaborators in Korea, Finland, and the United States, has now identified the missing anatomical gateway. The researchers discovered microscopic openings in the arachnoid membrane, which they named “arachnoid fenestrations”, that allow cerebrospinal fluid to pass directly into meningeal lymphatic vessels. The findings reveal the most detailed pathway yet for brain waste clearance and identify a drainage route that progressively deteriorates during aging but can be functionally restored in aged mice.

An international team led by the University of Lübeck has presented the largest genetic study of Parkinson's disease to date, part of the Global Parkinson's Genetics Program (GP2). Analysing data from almost 100,000 people across eleven population groups worldwide, the researchers show that disease-causing genetic variants occur with very different frequencies depending on ancestry. Because genetic research has so far focused mainly on people of European descent, disease causes in other populations often go undetected, excluding them from new, genetically targeted therapies. The study provides a basis for making diagnostics and precision medicine work for people with Parkinson's everywhere.

Kyoto, Japan -- Synucleinopathies are a group of neurodegenerative disorders that includes serious conditions such as Parkinson's disease and dementia with Lewy bodies. There are currently no cures for these disorders and treatment is limited to mitigating symptoms. Recently, antibody-based therapies have attracted considerable attention, but alternative approaches are still necessary.

Therapy development for synucleinopathies tends to target the alpha-synuclein protein, αSyn, the abnormal aggregation of which is a hallmark of these diseases. However, targeting this protein using conventional strategies for drug discovery is stymied by the molecule's lack of a stable three-dimensional structure, which cultivates aggregation.

Interested in understanding how abnormal protein aggregation drives neurodegeneration, a team of researchers at Kyoto University had an idea that was both scientifically intriguing and therapeutically promising: could RNA aptamers -- often described as "chemical antibodies" -- directly recognize αSyn's disordered regions and suppress pathological aggregation?

In preclinical tests, the compound from UC San Diego startup Sinopia Biosciences boosted the standard treatment’s benefits while counteracting debilitating side effects.

Using a groundbreaking imaging technique, a University of Houston chemist is uncovering how copper imbalances in the body may contribute to neurodegenerative diseases such as Alzheimer's, Parkinson's and ALS.